Published in final edited form as:

J Dermatol Sci. 2015 March ; 77(3): 156–165. doi:10.1016/j.jdermsci.2015.01.001.

Gene Expression Profiling in Pachyonychia Congenita Skin

Yu-An Cao¹, Robyn P. Hickerson^{1, #}, Brandon L. Seegmiller¹, Dmitry Grapov², Maren M. Gross³, Marc R. Bessette³, Brett S. Phinney², Manuel A. Flores¹, Tycho J. Speaker¹, Annaleen Vermeulen³, Albert A. Bravo⁴, Anna L. Bruckner⁵, Leonard M. Milstone⁶, Mary E. Schwartz⁷, Robert H. Rice², and Roger L. Kaspar^{1, *}

¹TransDerm Inc., Santa Cruz, CA 95060, USA

²University of California at Davis, Davis, CA 95616, USA

³Dharmacon part of GE Healthcare, Lafayette, CO 80026, USA

⁴Podiatric Medicine and Surgery, Pittsfield, MA 01201, USA

⁵University of Colorado School of Medicine, Aurora, CO 80045, USA

⁶Yale University, New Haven, CT 06520, USA

⁷Pachyonychia Congenita Project, Salt Lake City, UT 84109, USA

Abstract

Background—Pachyonychia congenita (PC) is a skin disorder resulting from mutations in keratin (K) proteins including K6a, K6b, K16, and K17. One of the major symptoms is painful plantar keratoderma. The pathogenic sequelae resulting from the keratin mutations remain unclear.

Objective—To better understand PC pathogenesis.

Methods—RNA profiling was performed on biopsies taken from PC-involved and uninvolved plantar skin of seven genotyped PC patients (two K6a, one K6b, three K16, and one K17) as well as from control volunteers. Protein profiling was generated from tape-stripping samples.

Results—A comparison of PC-involved skin biopsies to adjacent uninvolved plantar skin identified 112 differentially-expressed mRNAs common to patient groups harboring K6 (*i.e.*, both K6a and K6b) and K16 mutations. Among these mRNAs, 25 encode structural proteins including keratins, small proline-rich and late cornified envelope proteins, 20 are related to metabolism and 16 encode proteases, peptidases, and their inhibitors including kallikrein-related peptidases (*KLKs*), and serine protease inhibitors (*SERPINS*). mRNAs were also identified to be differentially

© 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd.

*To whom correspondence should be sent, 2161 Delaware Ave., Santa Cruz, CA 95060, USA, 831 420-1684, roger.kaspar@transderm.com.

#Current address: Centre for Dermatology and Genetic Medicine, Division of Molecular Medicine, University of Dundee, Dundee DD1 5EH, Scotland UK

Conflict of Interest

None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

expressed only in K6 (81) or K16 (141) patient samples. Furthermore, 13 mRNAs were identified that may be involved in pain including nociception and neuropathy. Protein profiling, comparing three K6a plantar tape-stripping samples to non-PC controls, showed changes in the PC corneocytes similar, but not identical, to the mRNA analysis.

Conclusion—Many differentially-expressed genes identified in PC-involved skin encode components critical for skin barrier homeostasis including keratinocyte proliferation, differentiation, cornification, and desquamation. The profiling data provide a foundation for unraveling the pathogenesis of PC and identifying targets for developing effective PC therapeutics.

Introduction

Pachyonychia congenita (PC) is a rare keratinization disorder resulting from autosomal dominant-negative mutations in keratin genes that are expressed in epithelial tissues [1–3]. Symptoms include thickened dystrophic nails, palmoplantar keratoderma, leukokeratosis, and follicular hyperkeratosis [4–6]. The major patient complaint is painful plantar keratoderma (possibly due to fissuring, secondary infections, increased pressure on nerve endings, underlying blistering and/or cutaneous thromboses [7–10]), where intense pain negatively impacts quality of life and often necessitates ambulatory aides and pain medication.

Keratins heterodimerize and further associate to form intermediate filaments, which provide mechanical strength and resilience to epithelial cells and tissues [11, 12]. Mutant keratins negatively impact skin structure and function, at least in part, by destabilizing the existing intermediate filament networks within cells [13–15], resulting in faulty intermediate filaments and cell fragility, which can lead to skin disorders including epidermolytic ichthyosis (also known as epidermolytic hyperkeratosis, caused by keratin (*KRT*) 1/*KRT10* gene mutations) [16, 17], epidermolysis bullosa simplex (*KRT5/KRT14*) [18, 19], and PC (*KRT6A/6B/16/17*) [1, 2, 5]. The majority of PC mutations are heterozygous missense or small insertion/deletion mutations that disrupt cytoskeletal function, presumably by preventing proper protein/protein interactions [20, 21]. In PC, this manifests as hyperplasia and hyperkeratosis in the subset of differentiated epithelial tissues in which mutant keratins including K6a, K6b, K16 and K17 are predominantly expressed [5], specifically in the palmoplantar epidermis, nail bed, oral mucosa, and the pilosebaceous unit. Surprisingly, *Krt16* knockout mice exhibit palmoplantar keratoderma (PPK)-like lesions, one of the hallmark features of PC [9, 22], in the absence of keratin mutations, suggesting that the pathogenesis of PC is more complex than previously appreciated.

In this study, we performed gene expression microarray analysis of RNA extracted from PC patient biopsies to examine changes in mRNA expression in PC-involved versus uninvolved and non-PC plantar skin to better understand the pathogenesis of PC at the molecular level, including the intense idiopathic pain associated with plantar keratoderma. Proteomic profiling of stratum corneum supported the findings herein.

Materials and Methods

Subjects

Seven patients from the International PC Research Registry (IPCRR) were identified by the Pachyonychia Congentia Project (www.pachyonychia.org) for evaluation in this study. Specific mutations in all seven IPCRR patients were previously identified, and the genotyping results were confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. The mutations of the participating PC patients are shown in Table I. Using local anesthesia, a matched pair of 3 or 4 mm full-thickness plantar skin punch biopsies, one from PC-involved skin and the other from adjacent uninvolved skin (typically within 1–2 cm but as far as 5 cm), was collected from each patient listed in Table I. The biopsy sites for one of the PC patients (IPCRR #1009, harbors a K16 R127C mutation) are shown in Fig. 1. Plantar biopsies from two healthy, non-PC volunteers (controls) were also collected from locations corresponding to the involved and uninvolved sites in PC patients. Biopsies were obtained using standard surgical techniques with patient consent under W-IRB #2004/0468/1057496.

RNA extraction and quantitative RT-PCR

Biopsied skin samples were collected and mechanically disrupted in a FASTprep24 (MPBio, Santa Ana, CA) with Lysing Matrix D as previously described [22, 23]. Total RNA was isolated using the RNeasy Mini Plus kit (Qiagen), according to manufacturer's instructions. Total RNA (up to 1 µg) isolated from skin samples was reverse transcribed with random hexamer primers using the Superscript III First-Strand Synthesis System (Life Technologies, Grand Island, NY) following the manufacturer's instructions.

Quantitative RT-PCR was performed on cDNAs (diluted 25-fold) from PC-involved and uninvolved biopsies of four patients (IPCRR #8, 233, 1009, and 1015). *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase), *KLK10*, *RGS20*, small proline-rich protein 1a (*SPRR1a*), *ADAM23*, *FABP5*, *RND3*, and *IFRD1* inventoried TaqMan gene expression assays were obtained from Applied Biosystems (ABI, Foster City, CA). Samples were analyzed using the ABI 7500 Fast Real-Time PCR System under standard conditions. The data were analyzed with the Applied Biosystem's Sequence Detection software (version 1.4) and reported as relative quantitation using *GAPDH* mRNA as the reference gene. All data points reported for individual patients are the mean of three replicate assays and changes in mRNA expression levels in PC-involved versus uninvolved are displayed as mean $\pm$ standard deviation (n=4).

RNA profiling

RNA profiling was performed on RNA samples from all 7 patients listed in Table I as described in Supplemental Materials and Methods Briefly, total RNA (100 to 200 µl of 50 ng/µl per sample) was processed following Agilent's (Santa Clara, CA) Two-Color Microarray-Based Gene Expression Analysis Protocol (Version 5.7). The Cy3- and Cy5-labeled and amplified cRNA were quantified using a NanoDrop 1000 UV-Vis spectrophotometer (Thermo Scientific, Waltham, MA). In some cases the above procedure was repeated on a different day and then respective samples were pooled and quantified

before hybridization (see Table SI). 627 to 825 ng of each cRNA sample was hybridized to Agilent 4×44K Human Whole Genome Gene Expression microarrays (part # G4112F). Data were extracted from the scanned images using Agilent Feature Extraction and imported into Rosetta (Kirkland, WA) Resolver (v7.2.2.0). For the differential expression analysis, fold changes and p-values were computed for each two-channel experiment using Rosetta's standard ratio experiment pipeline. Rosetta performs a two-sided, two-sample t-test on the means of the probe intensities corresponding to a single gene in each channel. The null hypothesis is that there is no fold change between the genes in the two channels. The p-values were corrected using Benjamini-Hochberg Multiple Test Correction [24] (for more information, see Whole Genome Microarray Processing and Table SI in Supplementary Materials and Methods). The full RNA profiling dataset has been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) site (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63326). An Excel file containing the subset of these data used for this study is provided in Supplemental Material.

Differentially-expressed genes were identified via two rounds of selection. For the first round, all genes with p-values and absolute fold changes satisfying the criteria of statistical significance (p-value < 0.1 and absolute fold change > 3.5 compared to matched PC-uninvolved skin) in at least one of three patients in either the K6 or K16 phenotypic group were selected. For the second round of selection, fold changes of individual genes that were selected in the first round were averaged within their respective K6 or K16 patient group using Student's t-test. The average fold changes were then filtered, limiting the set to those showing changes > 3.5-fold. This method of selection was chosen based on the limited number of PC skin samples available for the study. Due to the small sample size, patient-to-patient variability and the limiting amount of RNA extractable from 3–4 mm punch biopsies (maximum recommended to minimize scarring and other complications to patients), a more rigorous statistical analysis was not possible. Differentially-expressed genes common to K6 and K16 patients or unique to either K6 or K16 patients were sorted using Microsoft Office Excel. To identify differentially-expressed genes related to pain and neuropathy, a screening limit of 2-fold change in transcript levels was used, as described in the footnote for Tables SIII and SV.

Immunohistochemistry

Biopsied skin, embedded and frozen in optimal cutting temperature (O.C.T.) medium, was cryosectioned to 10 µm. Frozen skin sections were fixed (20 min in acetone at –20°C) and then incubated overnight at 4°C with SPRR1a primary antibody (rabbit polyclonal, affinity purified for amino acids 40–89, Abcam, Cambridge, MA) diluted 1:300 to a concentration of 3 µg/mL in PBS containing 0.025% Triton-X 100 (PBST). Rinsed sections were incubated for 3 h with Alexa Fluor-546 goat anti-rabbit secondary antibody (Life Technologies) in PBST. The sections were rinsed and mounted with Hydromount containing 4',6-diamidino-2-phenylindole (DAPI, 1 µg/mL; Sigma-Aldrich, St. Louis, MO) to facilitate visualization of nuclei. Sections were imaged using a Zeiss Axio Observer.A1 inverted fluorescence microscope equipped with FITC, Cy3 and DAPI filter sets.

Proteomic profiling

Using five successive 2.2 cm tape circles (D-Squame Pro Kits, CuDerm Corp, Dallas, TX), samples of plantar epidermis were collected from the heel and arch (analyzed separately) of three K6a N171K genotyped patients and from three healthy non-PC control subjects. Corneocytes were eluted from the tapes by immersion overnight in 2% sodium dodecyl sulfate, 0.1 M sodium phosphate pH 7.8, rinsed twice in the same solution, reduced and alkylated with iodoacetamide, precipitated with ethanol and digested with stabilized bovine trypsin [25] in 0.1 M ammonium bicarbonate/10% acetonitrile. Peptides were analyzed using a Thermo-Finnigan LTQ iontrap mass spectrometer, essentially as previously described [26]. X! Tandem was set up to search a March 11, 2013 Uniprot human database (91,573 proteins), appended to an identical but reversed database for calculating false discovery rates. Scaffold (version Scaffold_4.2.1, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. Protein identifications were accepted if they could be established at greater than 95% probability (protein decoy false discovery rate 4%; peptide decoy false discovery rate 0.6%). Proteins sharing significant peptide evidence were grouped into clusters, where spectral counts were adjusted for shared peptides using the weighted peptide option in Scaffold. This option appropriates a percentage of each count divided among the protein groups that share that peptide. The formulation for that percentage for peptide(i) assigned to protein(j) is $PPS(j)/\sum(PPS(1..n))$, where $PPS(j)$ is the sum of the peptides(1..m) for protein(j) and (1..n) is the set of proteins that contain peptide(i). The weighted spectral count is the sum of those percentages for each protein group. This is similar to method 3-a in Zhang et al [27], but Scaffold uses summed probabilities as normalizers instead of summed exclusive counts. The R statistical computing environment (v3.0.1) [28] was used to median normalize weighted spectral counts and to compare differences in protein abundance between subject groups using independent sample t-tests on shifted logarithm transformed data or quasi-poisson models without transformation. The two comparison approaches gave equivalent results, and spectral count differences for individual proteins were considered significant when $p < 0.1$. Illustrated are proteins for which significant changes were detected and where an average of at least 5 weighted spectral counts after normalization were detected in the most prevalent condition.

Results

Differentially-expressed genes in PC skin biopsies are clustered on chromosomal loci

Using a microarray approach, 18,771 unique genes were surveyed, and differentially-expressed genes were identified (by fold change) in PC-involved vs. uninvolved biopsied skin. Fold changes in differentially-expressed transcripts were averaged according to genotype and plotted against chromosomal location (Fig. 2). This analysis did not take p-values into consideration due to the small sample sizes (seven total PC-involved vs. uninvolved pairs consisting of three K6 patients (two K6a and one K6b), three K16 and one K17, Table I). Differentially-expressed genes in common with the non-PC volunteer control samples (potentially false positives) were removed from the analysis. Heterogeneity in gene expression levels was observed among all patients including those within a given genotype (*e.g.*, within K6 or K16 patient groups). Compared to changes in healthy non-PC volunteer

control matched biopsies (corresponding to the general location of PC-involved and uninvolved skin biopsies), there were several obvious hotspots on the chromosomes where gene expression levels were markedly altered, the most dramatic being the epidermal differentiation complex (EDC) on chromosome 1 (1q21), where 11 genes in K6 patients and 5 genes in K16 patients were upregulated by greater than 8-fold, respectively. These include *S100A*, *SPRR*, and late cornified envelope (*LCE*) protein genes. Other hotspots include the type I keratin cluster on chromosome 17 (17q12-q21) and the type II keratin cluster on chromosome 12 (12q11-q13). *KRT6A*, *KRT6B*, *KRT6C* and *KRT75* were among the most upregulated type II keratin genes in PC patients, while various type I keratin genes were differentially expressed among the patient groups (Fig. 2).

Classification of differentially-expressed genes

Using the cut-off criteria of statistical significance of p-value ≤ 0.1 and an average fold change of ≥ 3.5 when compared to matched PC-uninvolved skin biopsies for a given patient, a total of 193 genes were identified in the K6 patient group and 253 genes in the K16 group. Of these genes, 112 are common to both K6 and K16 patient groups, 81 genes are differentially expressed in the K6 genotype alone and 141 genes are found only in K16 patient samples (Fig. 3).

The 112 differentially-regulated genes shared by genotypes K6 and K16 were classified into nine categories based on gene ontology (Fig. 3). Detailed classification information, including chromosomal location and primary function, on all 112 genes is listed by category in Table SII and genes with an absolute fold change greater than 10 are summarized in Table II. As only one biopsy for a K17 patient was available, the dataset from this patient was excluded from the analysis. The hotspots of differentially-expressed genes (shown in Fig. 2) were confirmed using the cut-off criteria of p-value ≤ 0.1 and average fold change ≥ 3.5 , with 11 highly differentially-expressed genes clustering on the 1q21 locus and encoding either antimicrobial and inflammatory (*S100A8*, *S100A9*, *S100A7*, and *S100A7L1*) or structural (*LCE3A*, *LCE3D*, *Involucrin (IVL)*, *SPRR3*, *SPRR1A*, *SPRR1B*, and *SPRR2C*) proteins (Table SII). Among the 10 cytokeratin genes on either the type I or II cluster, transcripts of *KRT6A*, *KRT6B*, and *KRT6C* increased by 26-, 50-, and 30-fold, respectively. Other keratins such as *KRT16* and *KRT17*, *KRT75*, *KRT79*, *KRT80*, and *KRT85* are also upregulated significantly, whereas *KRT2* is downregulated and *KRT1* and *KRT10* are unchanged.

In the category of proteases, peptidases, and their inhibitors, two kallikrein-related peptidases (*KLK10* and *KLK5*; 5.7- and 5.0-fold changes, respectively), one chymotrypsin (*CTRB2*, 3.8-fold) and one metallopeptidase (*ADAM23*, 5.8-fold) are upregulated in PC-involved skin. Cathepsins, a class of proteases, are largely unchanged or slightly decreased (data not shown). Strikingly, many genes encoding protease inhibitors are upregulated including secretory leukocyte peptidase inhibitor (*SLPI*, 6.9-fold), skin-derived peptidase inhibitor 3 (*PI3*, also called elafin, 29-fold), cystatin A (*CSTA* or stefin A, 4.5-fold), serine peptidase inhibitor, Kazal type 6 (*SPINK6*, 20-fold), and three members from the SERPIN family (*SERPINS* B3, B4, and B13; 12-, 11-, and 5.8-fold, respectively). Transcripts of genes responsible for cell-cell adhesion such as corneodesmosin (*CDSN*), desmocollin 2

(*DSC2*), and gap junction beta 2 protein (*GJB2* also known as connexin 26) are also increased significantly. Several of the differentially-expressed genes are related to either lipid biogenesis or hydrolysis such as lipoprotein lipase (*LPL*), perilipin (*PLIN*), elongation of long chain fatty acids family member 7 (*ELOVL7*), and *KIAA1881* (Table SII).

Genes that are differentially expressed exclusively in either K6 or K16 patients were similarly classified and information on these genes is listed in Tables SIII and SIV (compare with Table SII). Notably, *KRT9* is dramatically downregulated by 22-fold in the K6 patient group (n=3) while unchanged in K16 patients (our related finding of a reciprocal correlation between *KRT6* and *KRT9* expression will be published elsewhere, Kaspar *et al.*, submitted). On the other hand, *KRT15* (7.6-fold), *KRT18* (4.7-fold) and *KRT19* (16-fold) are dramatically downregulated in K16 patients compared to minor changes (3.5-fold) in K6a patients (n=3), and therefore do not meet the selection cut-off criterion (3.5). Unexpectedly, several immunoglobulin genes (*IGHG4*, *IGLV2-14*, *IGHA2*, *IGLL1*, *IGJ*, and *IGKV1-5*) are upregulated in only K6 patients while only one, *IGH@*, is upregulated in both K6 and K16 patients (Tables SII and SIII).

Alteration of pain-relevant gene expression in PC-involved skin

Since persistent severe pain is the most problematic symptom for PC patients, genes with putative roles in nociception and neuropathy pathways were specifically investigated. Upregulation of 12 pain-related genes was observed in PC-involved skin compared to the uninvolved samples (Table SV). Of particular note, *SPRR1A* (11-fold, n=6), *KLK10* (5.7-fold, n=6), and regulator of G-protein signaling 20 (*RGS20*) (5-fold, n=6) are common to both K6 and K16 patients (Table SV), while *KLK12* (31-fold, n=3) appears to be specific to K6 patients (Tables SIII and SV).

To confirm the microarray results, RT-qPCR was performed on seven genes identified as differentially expressed by the microarray analysis that are potentially involved in nociception and neuropathy pathways. The RT-qPCR results of *KLK10*, *RGS20*, *SPRR1A*, *ADAM23*, *FABP5*, *RND3*, and *IFRD1* revealed similar fold changes compared to microarray analysis (Fig. 4A). *SPRR1A*, a gene encoding a structural protein but also related to neuropathy [29], was further subjected to immunohistochemical staining and exhibited increased protein levels in PC-involved skin sections compared to uninvolved (Fig. 4B & D). These results are in agreement with the increased RNA levels observed by RNA profiling and RT-qPCR analysis.

Proteomic analysis

To investigate expression differences at the protein level, samples of plantar callus from three PC patients with K6a N171K mutations were compared to normal control subjects by shotgun proteomics. The 37 proteins with significantly different expression present in at least moderate amounts (5 peptides or more in the most prominent condition) are listed in Table SVI and a subset graphically presented in Fig. 5. The most striking change was the evident suppression of K9 in the PC state. This was accompanied by suppression of the much less prominent desmocollin-1 and arachidonate 12-lipoxygenase (12R type). By contrast, keratins expressed at higher levels in the PC samples included K5, K6a, K14 and

K1. In addition, transglutaminases 1 and 3, S100A9 (as well as A7 and A8), SPRR2G (as well as 2F and 2D) are also substantially higher in the normal epidermis; also higher are the keratinocyte proteins gasdermin-A (10.7-fold), LCE 1B (11.5-fold), skin specific protein 2F (2.2-fold), filaggrin (4.6-fold), histidine ammonia lyase (17-fold), SERPINB3 (53.4-fold) and desmoglein-1 (1.8-fold) (Table SVI). Of the 37 proteins with significant changes (p-value<0.1), mRNAs for nine change in the same direction as observed in the DNA microarray experiments, where the rest were not observed with one exception. Unlike at the protein level, cornifin mRNA is nearly 4-fold higher in PC samples. Several prominent keratins (K6b, K16, K17) are seen to change in the same direction as their mRNAs but the p-values are 0.11–0.13 due to variability in the peptide counts and are therefore not included.

Discussion

PC plantar keratoderma is extremely painful, compromises patient mobility, and is the most problematic feature according to patients [4–6]. Unfortunately, the complex pathological mechanisms of disease progression are only now being elucidated, and no effective approved therapies exist that target the underlying disease mechanism. Several potential PC mouse models have been generated by altering the expression of genes associated with PC, including *Krt6a*, *Krt6b*, *Krt16* and *Krt17* [9, 14, 22, 30–34]. Surprisingly, among these models, only the *Krt16*-null mice exhibit palmoplantar keratoderma (PPK) with a possible decrease in overall mobility, potentially due to discomfort from painful keratoderma [9, 22].

In the current study, global gene expression profiling was performed on RNA extracted from PC patient skin biopsies. Differentially-expressed mRNA transcripts were identified in PC-involved versus uninvolved skin and classified into several major functional categories (specific to either the K6 or K16 genotype or common to both), including structural proteins, metabolism- or immune response-related proteins, proteases and peptidases and their inhibitors. Interestingly, these genes overlap extensively with those differentially expressed in the *Krt16*-null mouse model that exhibits paw keratoderma [9] and include genes involved in maintaining the mechanical integrity of the skin and desquamation [22]. Protein profiling on tape-stripping samples of PC patient plantar scale compared to non-PC control subjects revealed complementary, but not identical, results. The differences in the RNA profiling and proteomics analyses could be due to several reasons including: 1. the proteomic samples were obtained from tape-stripping of the stratum corneum whereas RNA profiling used full-thickness skin biopsies; 2. the proteomic samples were only from patients harboring the K6a N171K mutation and clear differences in RNA profiling are observed between patient groups (see Tables SIII and SIV); 3. the RNA profiling study was designed to compare intra-patient PC-involved to adjacent PC-uninvolved skin biopsies, whereas the proteomics compared PC skin samples to non-PC control subjects; and 4. the level of sensitivity of the proteomics analysis is lower than for the RNA profiling analysis.

Keratins form filamentous fibers that provide strength and stability to keratinocytes and the epidermis. Unlike the majority of keratins, K6, K16, and K17 are “inducible” and their expression can be rapidly switched on after stress or injury. In PC-involved skin biopsies, marked increases are observed in the transcript levels of the *KRT6A*, *KRT6B*, *KRT16*, and

KRT17 genes, mutations in which are known to cause PC [35]. It is plausible that mechanical forces acting on the skin (e.g., walking or friction from shoes) lead to upregulation of both wild-type and mutant forms of these keratins and that faulty intermediate filament formation due to mutant keratin incorporation into the fibers and/or the presence of free unincorporated mutant keratin protein may trigger the molecular pathogenesis leading to the PC phenotype [14, 15]. The structurally weakened PC keratinocytes and correspondingly compromised skin tissue are likely more prone to injury, thus increasing susceptibility to further insult and subsequent expression of additional mutant keratin as part of the wound healing response, resulting in a destructive downward cycle.

Non-PC-related keratins were also identified to be differentially expressed in involved vs. uninvolved skin. Unexpectedly, the hair follicle-associated keratins *KRT75* (formerly known as *KRT6hf*) and *KRT85* (also known as *KRTHB5*) are markedly increased in PC-involved skin. K9, a keratin that is abundantly and specifically expressed in terminally differentiating keratinocytes of palmoplantar epidermis, is dramatically reduced in the involved skin of K6, but not K16 or K17 patients (see also Kaspar et al., submitted for publication, for determination of absolute K9 and other keratin mRNA levels in PC skin). This observation was further confirmed by proteomic analysis in which a >60-fold K9 decrease was demonstrated in scale from K6a patients (see Fig. 5). In addition, downregulation of the basal cell keratins including *KRT15*, *KRT18* and *KRT19* is observed in K16 patients and unchanged or minimally altered in K6 patients. Genetic mouse models [34, 36] and the identification of causative gene mutations in human skin diseases [37–40] suggest that, individually or collectively, some of these keratins may be involved in PC pathogenesis.

Keratins have been implicated in the modulation of Akt and mTOR signaling pathways through direct physical interaction with the adapter protein 14-3-3 σ (stratiferin) [41], AMP-activated protein kinase (AMPK) [42] and Akt/PKB [43, 44], or via transcriptional regulation of the effector genes in the pathway [14, 45]. Previous studies on the regulation of nociceptive mechanisms show that sensory axonal protein synthesis also occurs under the control of the mTOR signaling pathway [47–49]. It would be intriguing to investigate the activation status of the mTOR pathway in PC-involved skin and whether it may contribute to the persistent pain experienced by PC patients.

Three clear clusters of induced gene expression are observed in PC-involved skin (see Fig. 2). In addition to the Type I and Type II keratin clusters, the EDC cluster (on chromosome 1q21) clearly stands out. The EDC comprises a large number of non-keratin genes involved in the maturation of the human epidermis [51, 52], including the formation of the cornified cell envelope. Many of the overexpressed EDC genes encode key structural players in stratum corneum formation including involucrin, loricrin, SPRRs, elafin, CSTA, LCEs and desmosomal proteins [53, 54], whose abnormal synthesis can result in inherited keratodermas [54–56]. These results are in general agreement with the increased protein levels observed in proteomic analysis of tape stripping samples obtained from PC scale as well as in other human skin disorders where the barrier is breached [57, 58]. The mechanism of coordinated upregulation of these clustered EDC genes during keratinocyte differentiation

or following barrier breach remains to be elucidated but epigenetic factors, such as DNA methylation, may be involved [58].

In normal human skin, homeostasis exists as terminally-differentiated corneocytes are shed (desquamation) and replaced by underlying differentiating keratinocytes, resulting in a relatively constant thickness of the epidermis [59, 60]. Desquamation is mediated by desmosomes as well as various proteases and protease inhibitors, many of which are upregulated in PC-involved skin. *DSC2* and *CDSN*, two major components of desmosome junctions, are significantly upregulated and may hinder desquamation. Furthermore, the proteases *KLK5* (serves as a primary regulator of the stratum corneum kallikrein cascade to cleave components of desmosomes and initiate desquamation [59, 61, 62]), *KLK10*, chymotrypsinogen B2 (*CTRB2*), and metallopeptidase domain 23 (*ADAM23*) are also upregulated. Some proteases, however, such as cathepsins remained unchanged or are slightly decreased (data not shown).

Protease activity can be controlled by various inhibitors, many of which, including *SPINK6*, SERPINs (*B3*, *B4*, and *B13*), elafin, and SLPI, are markedly upregulated. These protease inhibitors have distinct localization patterns, e.g., SERPINs are intracellular inhibitors that may have a role in protecting tissue from proteolysis [63, 64], while SPINKs are secreted and act extracellularly [65, 66]. Similar proteomics findings were observed from tape-stripping PC-involved skin compared to control skin. In addition, *CSTA*, a cysteine protease inhibitor present in skin and sweat that impedes corneodesmosome breakdown [67], is also upregulated in PC-involved skin biopsies.

Abnormal expression of these proteases and/or their inhibitors has the potential to dramatically change the state of desquamation, altering the equilibrium and the thickness of the stratum corneum. For example, mutations in the *SPINK5* gene cause Netherton syndrome, a severe disorder characterized by accelerated desquamation and dramatic skin peeling, defective keratinization, hair shaft defects, and recurrent infections [68, 69]. Accelerated corneocyte desquamation is also observed in palmoplantar hypokeratosis resulting from decreased expression of *SPINK5* and corneodesmosin, along with an increased expression of *KLK5* [70]. Conversely, delayed desquamation and palmoplantar keratoderma are observed with mutations in genes encoding the desquamation-related protease cathepsin C [71] or adhesion protein *GJB6* (also known as connexin-30) [72, 73]. Although it is difficult to assess the net activity of the proteases such as *KLK5* in the stratum corneum, it is reasonable to speculate that protease activity is suppressed and desquamation impaired in PC-involved skin, given the broad spectrum of these induced protease inhibitors (SERPINs, *SPINK6*, elafin, SLPI, and *CSTA*), the extent of this upregulation, and the increased thickness of PC-involved skin.

The intense pain associated with plantar keratoderma is the most problematic symptom for PC patients. Surprisingly, only a few genes potentially related to nociception and neuropathy appear to be differentially-expressed in PC-involved skin (similar results were also obtained in less stringent screens of the data). Among the upregulated “pain-related” genes identified, *KLK10* catalyzes the production of bradykinin, which initiates pain sensation after binding its receptor on nerve fiber endings [74]. Furthermore, *SPRR1a*, one of the important

structural proteins expressed in keratinocytes, is also expressed by neurons and promotes axonal outgrowth, guidance, and branching [75]. It is unclear, however, whether increased *SPRR1A* expression, along with other neuropathy-related genes, directly affects plantar pain [10]. In addition, the increased expression of antimicrobial peptides such as defensins (*DEFB4* and *DEFB103A*), 2'-5'-oligoadenylate synthetase-like (*OASL*), S100 proteins (A7, A8 and A9), and the immunoglobulin genes suggest the presence of infection (fungal and/or bacteria colonization) [10] and inflammation. In the recently described *Krt16*-null mouse model [9, 22], inflammation and increased numbers of infiltrating immune cells were observed in the hindpaws along with reduced mobility and possibly pain. These data suggest that inflammation, which might potentiate pain sensation from mechanical stress on the impaired skin barrier, may be a part of PC pathogenesis. To investigate the role of inflammation in PC, preliminary immunohistochemical staining has been performed on a small number of PC patient samples. Although some patients appear to have immune infiltrates, the small sample size and high patient-to-patient variability preclude firm conclusions and additional studies with greater numbers of PC and control biopsies are required.

Gene profiling studies have been performed in other skin disorders, notably psoriasis [76, 77]. There is some overlap in the upregulated genes that are common to both psoriatic and PC skin including *S100A7* (psoriasin) [52, 78], *S100A9*, *OASL*, *SERPINB3/B4*, *SPRR2C* [77], *IVL* and *CSTA* [76]. All of these known psoriatic markers are involved in atypical epidermal cellular organization and differentiation [76]. Down-regulation of *KRT18* and *KRT19* are also observed in psoriatic lesional skin [77]. Notably, in contrast to psoriatic skin in which inflammatory cytokines, interleukins, and other immunological components are highly upregulated [77], changes in immune-relevant gene expression are less evident in PC-involved skin with the exception of a few immunoglobulin genes (particularly in K6 patients) and the pro-inflammatory alarmins *S100A7/A8/A9* [79–82]. These striking gene expression similarities and differences in psoriatic and PC skin warrant further investigation.

In summary, this study identified dramatic changes in expression of a multitude of genes potentially related to PC pathogenesis. Many of these genes encode structural proteins, proteases, and protease inhibitors that are critical for cornification or desquamation, an imbalance in which likely leads to PC palmoplantar keratoderma. Fig. 6 schematically depicts how PC-relevant keratin mutations may ultimately lead to the observed keratoderma and pain, incorporating many of the molecular players identified in this study together with other published and unpublished observations. It is important to note that the sample size was small and the samples were collected in different batches; therefore, minimal statistics were utilized. The data generated from this study should form a framework for understanding the sequelae resulting from mutant keratin expression in PC skin and may lead to a rational approach for identifying appropriate therapies for PC patients.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the PC patients and other volunteers who donated skin biopsies, without which this study would not have been possible. We thank Drs. Irwin McLean (University of Dundee) and Sumedha Jayasena for thoughtful discussion and critical reading of the manuscript, Andrea Burgon for excellent technical and administrative support and Dr. Jean Tang (Stanford University) for skin biopsies. We thank the membership of the International PC Consortium (IPCC) for their useful comments throughout this project. This work was supported by the Pachyonychia Congenita Project (www.pachyonychia.org), a patient advocacy group committed to improving the lives of PC patients. This work was partially supported by NIH grants P42 ES04699 and U24 DK097154 to RHR and NIH NIAMS grants R44 ARO56559 and R43 ARO65895 to RLK.

References

1. Bowden PE, Haley JL, Kansky A, Rothnagel JA, Jones DO, Turner RJ. Mutation of a type II keratin gene (K6a) in pachyonychia congenita. *Nat Genet.* 1995; 10:363–365. [PubMed: 7545493]
2. McLean WH, Rugg EL, Lunny DP, Morley SM, Lane EB, Swensson O, et al. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. *Nat Genet.* 1995; 9:273–278. [PubMed: 7539673]
3. Smith FJ, Jonkman MF, van Goor H, Coleman CM, Covello SP, Uitto J, et al. A mutation in human keratin K6b produces a phenocopy of the K17 disorder pachyonychia congenita type 2. *Hum Mol Genet.* 1998; 7:1143–1148. [PubMed: 9618173]
4. Leachman SA, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, et al. Clinical and pathological features of pachyonychia congenita. *J Invest Dermatol Symp Proc.* 2005; 10:3–17.
5. McLean WH, Hansen CD, Eliason MJ, Smith FJ. The phenotypic and molecular genetic features of pachyonychia congenita. *The Journal of investigative dermatology.* 2011; 131:1015–1017. [PubMed: 21430705]
6. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. *Journal of the American Academy of Dermatology.* 2012; 67:680–686. [PubMed: 22264670]
7. Goldberg I, Sprecher E, Schwartz ME, Gaitini D. Comparative study of high-resolution multifrequency ultrasound of the plantar skin in patients with various types of hereditary palmoplantar keratoderma. *Dermatology.* 2013; 226:365–370. [PubMed: 24030314]
8. Dahl PR, Daoud MS, Su WP. Jadassohn-Lewandowski syndrome (pachyonychia congenita). *Seminars in dermatology.* 1995; 14:129–134. [PubMed: 7640192]
9. Lessard JC, Coulombe PA. Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders. *The Journal of investigative dermatology.* 2012; 132:1384–1391. [PubMed: 22336941]
10. Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. *Journal of dermatological science.* 2009; 56:82–88. [PubMed: 19699613]
11. Irvine AD, McLean WH. Human keratin diseases: the increasing spectrum of disease and subtlety of the phenotype-genotype correlation. *The British journal of dermatology.* 1999; 140:815–828. [PubMed: 10354017]
12. Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. *N Engl J Med.* 2004; 351:2087–2100. [PubMed: 15537907]
13. Owens DW, Wilson NJ, Hill AJ, Rugg EL, Porter RM, Hutcheson AM, et al. Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. *Journal of cell science.* 2004; 117:1989–1999. [PubMed: 15090596]
14. Koster MI. Building models for keratin disorders. *The Journal of investigative dermatology.* 2012; 132:1324–1326. [PubMed: 22499036]
15. Godsel LM, Hobbs RP, Green KJ. Intermediate filament assembly: dynamics to disease. *Trends in cell biology.* 2008; 18:28–37. [PubMed: 18083519]
16. Chassaing N, Kanitakis J, Sportich S, Cordier-Alex MP, Titeux M, Calvas P, et al. Generalized epidermolytic hyperkeratosis in two unrelated children from parents with localized linear form, and prenatal diagnosis. *J Invest Dermatol.* 2006; 126:2715–2717. [PubMed: 16990804]

17. Ross R, DiGiovanna JJ, Capaldi L, Argenyi Z, Fleckman P, Robinson-Bostom L. Histopathologic characterization of epidermolytic hyperkeratosis: a systematic review of histology from the National Registry for Ichthyosis and Related Skin Disorders. *J Am Acad Dermatol*. 2008; 59:86–90. [PubMed: 18571597]
18. Stephens K, Ehrlich P, Weaver M, Le R, Spencer A, Sybert VP. Primers for exon-specific amplification of the KRT5 gene: identification of novel and recurrent mutations in epidermolysis bullosa simplex patients. *J Invest Dermatol*. 1997; 108:349–353. [PubMed: 9036937]
19. Hut PH, vd Vlies P, Jonkman MF, Verlind E, Shimizu H, Buys CH, et al. Exempting homologous pseudogene sequences from polymerase chain reaction amplification allows genomic keratin 14 hotspot mutation analysis. *J Invest Dermatol*. 2000; 114:616–619. [PubMed: 10733662]
20. McLean WH, Smith FJ, Cassidy AJ. Insights into genotype-phenotype correlation in pachyonychia congenita from the human intermediate filament mutation database. *J Invest Dermatol Symp Proc*. 2005; 10:31–36.
21. Fu T, Leachman SA, Wilson NJ, Smith FJ, Schwartz ME, Tang JY. Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. *J Invest Dermatol*. 2011; 131:1025–1028. [PubMed: 21160496]
22. Lessard JC, Pina-Paz S, Rotty JD, Hickerson RP, Kaspar RL, Balmain A, et al. Keratin 16 regulates innate immunity in response to epidermal barrier breach. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:19537–19542. [PubMed: 24218583]
23. Garcia M, Larcher F, Hickerson RP, Baselga E, Leachman SA, Kaspar RL, et al. Development of skin-humanized mouse models of pachyonychia congenita. *J Invest Dermatol*. 2011; 131:1053–1060. [PubMed: 21150925]
24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995; 57:289–300.
25. Rice RH, Means GE, Brown WD. Stabilization of bovine trypsin by reductive methylation. *Biochim Biophys Acta*. 1977; 492:316–321. [PubMed: 560214]
26. Rice RH, Bradshaw KM, Durbin-Johnson BP, Rocke DM, Eigenheer RA, Phinney BS, et al. Distinguishing ichthyoses by protein profiling. *PLoS One*. 2013; 8(10):e75355. [PubMed: 24130705]
27. Zhang Y, Wen Z, Washburn MP, Florens L. Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. *Analytical chemistry*. 2010; 82:2272–2281. [PubMed: 20166708]
28. Team RDC. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2011.
29. Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2002; 22:1303–1315. [PubMed: 11850458]
30. Wong P, Colucci-Guyon E, Takahashi K, Gu C, Babinet C, Coulombe PA. Introducing a null mutation in the mouse K6alpha and K6beta genes reveals their essential structural role in the oral mucosa. *The Journal of cell biology*. 2000; 150:921–928. [PubMed: 10953016]
31. Wong P, Domergue R, Coulombe PA. Overcoming functional redundancy to elicit pachyonychia congenita-like nail lesions in transgenic mice. *Mol Cell Biol*. 2005; 25:197–205. [PubMed: 15601842]
32. Wojcik SM, Longley MA, Roop DR. Discovery of a novel murine keratin 6 (K6) isoform explains the absence of hair and nail defects in mice deficient for K6a and K6b. *The Journal of cell biology*. 2001; 154:619–630. [PubMed: 11489919]
33. McGowan KM, Tong X, Colucci-Guyon E, Langa F, Babinet C, Coulombe PA. Keratin 17 null mice exhibit age- and strain-dependent alopecia. *Genes Dev*. 2002; 16:1412–1422. [PubMed: 12050118]
34. Chen J, Jaeger K, Den Z, Koch PJ, Sundberg JP, Roop DR. Mice expressing a mutant Krt75 (K6hf) allele develop hair and nail defects resembling pachyonychia congenita. *The Journal of investigative dermatology*. 2008; 128:270–279. [PubMed: 17851587]

35. Alberts, B.; Johnson, A.; Lewis, J., et al. In *Molecular Biology of the Cell*. Garland Science; New York: 2002. The Self-Assembly and Dynamic Structure of Cytoskeletal Filaments.
36. Fu DJ, Thomson C, Lunny DP, Dopping-Hepenstal PJ, McGrath JA, Smith FJ, et al. Keratin 9 Is Required for the Structural Integrity and Terminal Differentiation of the Palmoplantar Epidermis. *J Invest Dermatol*. 2013
37. Naeem M, Wajid M, Lee K, Leal SM, Ahmad W. A mutation in the hair matrix and cuticle keratin KRTHB5 gene causes ectodermal dysplasia of hair and nail type. *Journal of medical genetics*. 2006; 43:274–279. [PubMed: 16525032]
38. Kobayashi S, Tanaka T, Matsuyoshi N, Imamura S. Keratin 9 point mutation in the pedigree of epidermolytic hereditary palmoplantar keratoderma perturbs keratin intermediate filament network formation. *FEBS Lett*. 1996; 386:149–155. [PubMed: 8647270]
39. Covello SP, Irvine AD, McKenna KE, Munro CS, Nevin NC, Smith FJ, et al. Mutations in keratin K9 in kindreds with epidermolytic palmoplantar keratoderma and epidemiology in Northern Ireland. *The Journal of investigative dermatology*. 1998; 111:1207–1209. [PubMed: 9856842]
40. Coleman CM, Munro CS, Smith FJ, Uitto J, McLean WH. Epidermolytic palmoplantar keratoderma due to a novel type of keratin mutation, a 3-bp insertion in the keratin 9 helix termination motif. *The British journal of dermatology*. 1999; 140:486–490. [PubMed: 10233272]
41. Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. *Nature*. 2006; 441:362–365. [PubMed: 16710422]
42. Vijayaraj P, Kroger C, Reuter U, Windoffer R, Leube RE, Magin TM. Keratins regulate protein biosynthesis through localization of GLUT1 and -3 upstream of AMP kinase and Raptor. *The Journal of cell biology*. 2009; 187:175–184. [PubMed: 19841136]
43. Galarneau L, Loranger A, Gilbert S, Marceau N. Keratins modulate hepatic cell adhesion, size and G1/S transition. *Exp Cell Res*. 2007; 313:179–194. [PubMed: 17112511]
44. Kellner JC, Coulombe PA. Keratins and protein synthesis: the plot thickens. *The Journal of cell biology*. 2009; 187:157–159. [PubMed: 19841134]
45. Ju JH, Yang W, Lee KM, Oh S, Nam K, Shim S, et al. Regulation of cell proliferation and migration by keratin19-induced nuclear import of early growth response-1 in breast cancer cells. *Clin Cancer Res*. 2013; 19:4335–4346. [PubMed: 23833298]
46. von Manteuffel SR, Dennis PB, Pullen N, Gingras AC, Sonenberg N, Thomas G. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. *Mol Cell Biol*. 1997; 17:5426–5436. [PubMed: 9271419]
47. Price TJ, Rashid MH, Millecamps M, Sanoja R, Entrena JM, Cervero F. Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. *J Neurosci*. 2007; 27:13958–13967. [PubMed: 18094233]
48. Jimenez-Diaz L, Geranton SM, Passmore GM, Leith JL, Fisher AS, Berliocchi L, et al. Local translation in primary afferent fibers regulates nociception. *PLoS ONE*. 2008; 3:e1961. [PubMed: 18398477]
49. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, et al. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. *J Neurosci*. 2009; 29:15017–15027. [PubMed: 19940197]
50. O'Toole E, Kaspar RL, Sprecher E, Schwartz ME, Rittié L. Pachyonychia Congenita Cornered: Report on the 11th Annual International Pachyonychia Congenita Consortium Meeting. *The Journal of investigative dermatology*. Submitted for publication.
51. Marenholz I, Volz A, Ziegler A, Davies A, Ragoussis I, Korge BP, et al. Genetic analysis of the epidermal differentiation complex (EDC) on human chromosome 1q21: chromosomal orientation, new markers, and a 6-Mb YAC contig. *Genomics*. 1996; 37:295–302. [PubMed: 8938441]
52. Hardas BD, Zhao X, Zhang J, Longqing X, Stoll S, Elder JT. Assignment of psoriasis to human chromosomal band 1q21: coordinate overexpression of clustered genes in psoriasis. *The Journal of investigative dermatology*. 1996; 106:753–758. [PubMed: 8618016]
53. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. *Nature reviews Molecular cell biology*. 2005; 6:328–340.

54. Ishida-Yamamoto A, Iizuka H. Structural organization of cornified cell envelopes and alterations in inherited skin disorders. *Experimental dermatology*. 1998; 7:1–10. [PubMed: 9517915]
55. Itin PH, Fistarol SK. Palmoplantar keratodermas. *Clinics in dermatology*. 2005; 23:15–22. [PubMed: 15708285]
56. Christiano AM. Frontiers in keratodermas: pushing the envelope. *Trends in genetics: TIG*. 1997; 13:227–233. [PubMed: 9196328]
57. Capon F, Semprini S, Chimenti S, Fabrizi G, Zambruno G, Murgia S, et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. *The Journal of investigative dermatology*. 2001; 116:728–730. [PubMed: 11348461]
58. Elder JT, Zhao X. Evidence for local control of gene expression in the epidermal differentiation complex. *Experimental dermatology*. 2002; 11:406–412. [PubMed: 12366693]
59. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. *J Invest Dermatol*. 1993; 101:200–204. [PubMed: 8393902]
60. Milstone LM. Epidermal desquamation. *Journal of dermatological science*. 2004; 36:131–140. [PubMed: 15541634]
61. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. *J Invest Dermatol*. 2004; 122:1235–1244. [PubMed: 15140227]
62. Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. *J Biol Chem*. 1999; 274:30033–30040. [PubMed: 10514489]
63. Fischer J, Meyer-Hoffert U. Regulation of kallikrein-related peptidases in the skin - from physiology to diseases to therapeutic options. *Thromb Haemost*. 2013; 110:442–449. [PubMed: 23446429]
64. Meyer-Hoffert U, Schroder JM. Epidermal proteases in the pathogenesis of rosacea. *J Invest Dermatol Symp Proc*. 2011; 15:16–23.
65. Ishida-Yamamoto A, Simon M, Kishibe M, Miyauchi Y, Takahashi H, Yoshida S, et al. Epidermal lamellar granules transport different cargoes as distinct aggregates. *J Invest Dermatol*. 2004; 122:1137–1144. [PubMed: 15140216]
66. Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, O'Brien TJ, et al. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. *J Invest Dermatol*. 2005; 124:360–366. [PubMed: 15675955]
67. Park JH, Schuchman EH. Acid ceramidase and human disease. *Biochim Biophys Acta*. 2006; 1758:2133–2138. [PubMed: 17064658]
68. Komatsu N, Takata M, Otsuki N, Ohka R, Amano O, Takehara K, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. *J Invest Dermatol*. 2002; 118:436–443. [PubMed: 11874482]
69. Di WL, Mellerio JE, Bernadis C, Harper J, Abdul-Wahab A, Ghani S, et al. Phase I study protocol for ex-vivo lentiviral gene therapy for the inherited skin disease, Netherton Syndrome. *Hum Gene Ther Clin Dev*. 2013
70. Kanitakis J, Lora V, Chouvet B, Zambruno G, Haftek M, Faure M. Circumscribed palmo-plantar hypokeratosis: a disease of desquamation? Immunohistological study of five cases and literature review. *J Eur Acad Dermatol Venereol*. 2011; 25:296–301. [PubMed: 20626532]
71. Kurban M, Cheng T, Wajid M, Kiuru M, Shimomura Y, Christiano AM. A novel mutation in the cathepsin C gene in a Pakistani family with Papillon-Lefevre syndrome. *J Eur Acad Dermatol Venereol*. 2010; 24:967–969. [PubMed: 20236208]
72. Ando Y, Tanaka T, Horiguchi Y, Ikai K, Tomono H. Hidrotic ectodermal dysplasia: a clinical and ultrastructural observation. *Dermatologica*. 1988; 176:205–211. [PubMed: 3378657]
73. Der Kaloustian VM. Hidrotic Ectodermal Dysplasia. 1993; 2
74. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. *Nature reviews Drug discovery*. 2004; 3:845–852.

75. Morris JS, Stein T, Pringle MA, Davies CR, Weber-Hall S, Ferrier RK, et al. Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. *J Cell Physiol.* 2006; 206:16–24. [PubMed: 15920758]
76. Kulski JK, Kenworthy W, Bellgard M, Taplin R, Okamoto K, Oka A, et al. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals. *Journal of molecular medicine.* 2005; 83:964–975. [PubMed: 16283139]
77. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. *The Journal of investigative dermatology.* 2012; 132:2552–2564. [PubMed: 22763790]
78. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. *The Journal of investigative dermatology.* 1991; 97:701–712. [PubMed: 1940442]
79. Wolf R, Mascia F, Dharamsi A, Howard OM, Cataisson C, Bliskovski V, et al. Gene from a psoriasis susceptibility locus primes the skin for inflammation. *Science translational medicine.* 2010; 2:61ra90.
80. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. *Biochemical pharmacology.* 2006; 72:1622–1631. [PubMed: 16846592]
81. Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the epidermis. *The Journal of investigative dermatology.* 2004; 123:23–33. [PubMed: 15191538]
82. Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximenez-Embun P, Guio-Carrion A, et al. S100A8–S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. *Immunity.* 2013; 39:1171–1181. [PubMed: 24332034]

Highlights

- Both mRNA and protein profiling of PC-involved skin biopsies to uninvolved plantar skin identified differentially-expressed genes.
- The differentially-expressed genes cluster into 9 different classes according to their primary functions.
- A model of the molecular pathways involved in PC pathogenesis is proposed.

Fig. 1. Physical locations of plantar biopsy sites for one of the participating patients (K16-R127C mutation)

Sites (involved and uninvolved) where biopsies were obtained (as described in Methods and Materials) are circled. Similar biopsy pairs were collected from all PC participants and non-PC volunteers (controls).

Fig. 2. Chromosomal location and hotspots for differentially-expressed genes in PC skin mRNA expression profiling results, comparing PC-involved and uninvolved skin biopsies obtained from genotyped patients, were grouped by keratin mutation (K6, $n=3$; K16, $n=3$; and K17, $n=1$). For each of the 18,771 unique genes represented in the microarray, the average fold change of transcripts in PC-involved skin vs. adjacent uninvolved skin was plotted against chromosomal location. Genes whose expression levels are markedly altered (usually by greater than 8-fold) are labeled. Three hotspots for highly differentially-expressed genes are shaded.

Fig. 3. Venn diagram and classification of differentially-expressed genes by genotype
mRNA profiling results were divided into K6 and K16 groups according to patient genotype. Genes satisfying the criteria of fold change ≥ 3.5 and p-value ≤ 0.1 (when compared to matched PC-uninvolved skin biopsies) were identified as differentially expressed (see Materials and Methods). Of the resulting 193 genes in K6 patients (n=3) and 253 genes in K16 patients (n=3), 112 are common to both K6 and K16 patient groups, while 81 genes are differentially expressed only in K6 patients and 141 genes only in K16 patients. The identified genes were classified into different categories with color coding (applies to pie chart) according to function.

Fig. 4. Validation of mRNA profiling results by RT-qPCR and immunohistochemistry Selected differentially-expressed genes identified by mRNA profiling that are potentially related to nociception and neuropathy were further analyzed by RT-qPCR to confirm the mRNA profiling findings. For each gene analyzed, RT-qPCR was performed (> three replicates) and the average fold change of expression levels (involved vs. uninvolved) was plotted as mean $\pm$ standard deviation (n=4) (A). SPRR1A was selected for further investigation by immunohistochemistry of frozen skin sections (10 μ m). Increased protein expression of SPRR1a (red) is observed in PC-involved skin biopsies (B) compared to uninvolved (D). Enlarged images of areas marked by squares are also shown (C and E). Nuclei were counterstained with DAPI (blue) Scale bar = 500 μ m.

Fig. 5. Differences in protein profile between PC and normal epidermis

Illustrated are the normalized weighted spectral counts of keratins (top) and other prominent keratinocyte proteins (bottom) from three subjects, each harboring the K6a N171K mutation.

Fig. 6. Proposed model of molecular pathways involved in PC pathogenesis

In healthy skin, keratinocyte cornification and desquamation exist in equilibrium to maintain the appropriate epithelium thickness. In PC, this process is imbalanced as exemplified by acanthosis associated with increased levels of structural (keratins, SPRRs, IVL, and late cornified envelope) and adhesion (CDSN, DSC2, and GJB2) proteins in the SC.

Desquamation is putatively delayed by inhibition of key desquamation enzymes such as KLK5, KLK7, and cathepsins, likely through increased production of protease inhibitors including SPINK6, SPINK5, elafin, SLPI, and SERPINs. This imbalance likely leads to the observed keratoderma. Mechanical stress acting on the altered skin barrier may trigger pain, potentiated by mTOR pathway activation, increased KLK10 and bradykinin levels and/or tissue damage caused by microbial colonization and infection in the skin.

Table I

IPCRR numbers and corresponding mutations of PC patients

IPCRR #	Mutation
8	K6a N171K
10	K6a N171K
661	K6b E472K
233	K16 R127G
1009	K16 R127C
1015	K16 R127C
394	K17 N92S

Table II

List of differentially-expressed genes identified in RNA profiling study common to K6 and K16 patient groups with absolute fold change* at least 10 and p-value less than 0.1

Gene Category	Genes
Cell proliferation, differentiation and apoptosis	GoS2
Immunity and immune response	S100A7, S100A7L1, S100A8, S100A9, DEFB4, DEFB103A, OASL, IGH@
Proteases, peptidases and inhibitors	PI3, SPINK6, SERPINB3, SERPINB4
Structural	ACTG2, KRT6A, KRT6B, KRT6C, K16, KRT75, LCE3A, LCE3D, SPRR1A, SPRR1B, SPRR2C, SPRR3
Transfer/carrier, transporter and channel	RHCG

* For absolute mean fold change of individual genes as well as a more comprehensive list of differentially-expressed genes, see Supplementary Table SII.